Quick Facts
Plain-English Summary
Tesamorelin (brand name Egrifta, manufactured by Theratechnologies) is the only GHRH analogue currently FDA-approved in the United States. It received approval in 2010 for the reduction of excess abdominal fat (visceral adiposity) in HIV-infected patients with antiretroviral-associated lipodystrophy. Unlike Sermorelin (29 amino acids) or modified GRF compounds, Tesamorelin is a stabilised analogue of full-length GHRH(1-44), with a trans-3-hexenoic acid group at the N-terminus that protects against enzymatic degradation.
Multiple Phase III RCTs have demonstrated statistically significant visceral fat reduction (~15–20% from baseline) and improvements in lipid profiles. Its use in non-HIV populations is off-label and increasingly explored in the longevity medicine space.
Tesamorelin is the only GHRH analogue with FDA approval, backed by multiple Phase III RCTs with rigorous clinical endpoints. This places it in a distinct evidentiary category from other peptides in this class.
The compound's primary approved indication is tightly defined: HIV-associated lipodystrophy caused by antiretroviral therapy. The translation of its visceral fat reduction effect to otherwise-healthy adults with metabolic syndrome is biologically plausible but not yet established through equivalent RCT data in non-HIV populations. This distinction is frequently blurred in longevity and biohacking contexts.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rodent PK studies | Established pharmacokinetic profile, GH stimulation characteristics, and IGF-1 response curves. Confirmed N-terminal modification confers DPP-IV resistance and extends plasma half-life versus native GHRH. | Preclinical |
| Rodent metabolic models | GH/IGF-1 axis activation confirmed across multiple rodent models. Preferential visceral fat mobilisation consistent with the mechanism of GH-driven lipolysis. | Preclinical |
| Primate studies | Visceral fat reduction effect confirmed in non-human primate models. Cardiovascular parameter improvements consistent with GH elevation. Animal data predicted the HIV lipodystrophy effect subsequently confirmed in clinical trials. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| LIPO-010 Phase III RCT | HIV patients with antiretroviral-associated lipodystrophy; tesamorelin 2 mg/day vs. placebo | — | Strong |
| LIPO-011 Phase III RCT | HIV patients with lipodystrophy; confirmatory trial with dual primary endpoints (VAT by CT and patient-reported outcomes) | — | Strong |
| 52-Week Phase III Extension | HIV lipodystrophy patients continuing from pivotal trials | — | Strong |
| Stanley et al. 2012 (non-HIV) | Healthy older adults (60+) with excess abdominal fat; small RCT | — | Preliminary |
Tesamorelin has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Safety profile established through Phase III clinical trials with large patient populations. Common adverse events include injection site reactions, peripheral oedema, arthralgia, myalgia, and carpal tunnel syndrome — consistent with known GH elevation effects. No increased cancer risk identified in controlled trials.
IGF-1 elevation can reduce insulin sensitivity. Glucose metabolism effects require monitoring, particularly in pre-diabetic patients. Patients on antiretrovirals may have altered pharmacokinetics affecting glucose regulation. Routine HbA1c and fasting glucose monitoring is recommended during treatment.
- Injection site reactions (pain, erythema, induration)
- Peripheral oedema
- Arthralgia and myalgia
- Carpal tunnel syndrome
- Paraesthesia and hypoaesthesia
- Nausea, dyspepsia
- Active or suspected malignancy
- Hypopituitarism
- Pregnancy and breastfeeding
- Disruption of the hypothalamic-pituitary axis (surgery, radiation, head trauma)
- Hypersensitivity to Tesamorelin or mannitol
Tesamorelin is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Tesamorelin for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
Prescribed Tesamorelin off-label for visceral adiposity by my anti-ageing MD. 6 months in: DEXA shows -12% visceral fat, IGF-1 up 55 points. This is the real deal — actual FDA-approved compound with RCT data. Different league from most peptides discussed here.
The Falutz NEJM paper is what everyone should read before dismissing or over-hyping this. The VAT reduction effect size is clinically meaningful.
Important context often missed: Tesamorelin was approved for HIV lipodystrophy — a specific metabolic condition caused by antiretroviral therapy. The translation to healthy adults or general obesity is biologically plausible but off-label. Know what you're doing.
Tesamorelin is compoundable in the US by 503A pharmacies under physician supervision. For those wanting a legally prescribed GHRH analogue with actual RCT data, this and Sermorelin are the only rational choices.
Correct. Everything else in this space is a grey-area research compound. Tesamorelin and Sermorelin are in a different category legally and clinically.
The structural distinction matters: Tesamorelin is a full-length GHRH(1-44) analogue versus Sermorelin and Mod GRF which are 1-29 fragments. Whether the additional 15 C-terminal amino acids confer any practical advantage beyond the N-terminal protection is not fully resolved.